Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Stage III Colon Cancer: early-phase trial registry

3 of 7 indexed Stage III Colon Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Stage III Colon Cancer: 7 US clinical trials tracked, 3 recruiting.

Stage III Colon Cancer is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.

Enrollment posture brief

Registry condition stage-iii-colon-cancer

OPEN 3 | RECR 43% | LATE 2 | EARLY 5 | RANK #2497 | SPON 3

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Stage III Colon Cancer (this)43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Stage III Colon Cancer

Stage III Colon Cancer lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage III Colon Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage III Colon Cancer is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage III Colon Cancer research.

    National Cancer Institute (NCI) accounts for 3 of 7 trials (42.9%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Stage III Colon Cancer enrolment sits around 54 participants.

    Median target enrolment is 54 among the 7 trials that report a genuine target (sentinel values excluded). 4 of those (57.1%) plan for fewer than 100 participants.

  4. Stage III Colon Cancer research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 22Phase 32

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 2

Named interventions

Most-linked intervention names on Stage III Colon Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

laboratory biomarker analysis Other
3 trials
leucovorin calcium Drug
2 trials
fluorouracil Drug
2 trials
oxaliplatin Drug
2 trials
resveratrol Drug
1 trials
modified vaccinia virus ankara vaccine expressing p53 Biological
1 trials
enzyme-linked immunosorbent assay Other
1 trials
immunoenzyme technique Other
1 trials

US sites by state

Facility locations filed on Stage III Colon Cancer trials. A trial with sites in several states counts in each.

New York 2 trials
California 2 trials
Texas 1 trials
Pennsylvania 1 trials
Michigan 1 trials
Massachusetts 1 trials
Arizona 1 trials
Arkansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage III Colon Cancer page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Colon Cancer condition card totals 7 registered trials; most-linked intervention laboratory biomarker analysis; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.